Abstract
Immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) have improved overall survival (OS) in patients (pts) with advanced melanoma, and neoadjuvant ICIs can induce tumor regression in pts with resectable melanoma. Targeting other co-inhibitory receptors, such as lymphocyte activation gene-3 (LAG-3) or T cell immunoglobulin and ITIM domain (TIGIT), or combining agents targeting multiple immune evasion mechanisms may enhance antitumor activity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
